Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib for Cancer Cachexia
NCT07146893Phase 1Not yet recruiting
- Sponsor
- University of Oklahoma
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selpercatinib in anorexia-cachexia syndrome (CACS), sponsored by University of Oklahoma. Primary endpoints: Mean changes in body weight at 12 weeks and Percentage of doses of selpercatinib taken on time at 12 weeks. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
selpercatinib
03
Conditions
anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on NCT07146893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07146893.